Aurinia Pharmaceuticals AUPH License, collaboration and royalty revenue — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's license, collaboration and royalty revenue — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's license, collaboration and royalty revenue — revenue?
- Aurinia Pharmaceuticals (AUPH) reported license, collaboration and royalty revenue — revenue of $4.14M in Q1 2026.
- How has Aurinia Pharmaceuticals's license, collaboration and royalty revenue — revenue changed year-over-year?
- Aurinia Pharmaceuticals's license, collaboration and royalty revenue — revenue increased by 66.1% year-over-year, from $2.49M to $4.14M.
- What is the long-term trend for Aurinia Pharmaceuticals's license, collaboration and royalty revenue — revenue?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's license, collaboration and royalty revenue — revenue has grown at a 216.3% compound annual growth rate (CAGR), from $117K to $11.71M.
- What does license, collaboration and royalty revenue — revenue mean?
- This metric represents the total revenue generated from licensing intellectual property, collaborative research agreements, and royalty payments derived from commercialized products. It reflects the company's ability to monetize its proprietary technology and partnerships without direct product sales. Monitoring this stream helps investors assess the success of strategic alliances and the long-term value of the company's patent portfolio.